Astellas Extends Deal With Regeneron For Antibody Technology Built Around Growing Oncology Portfolio
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Astellas has acknowledged that it is a late-comer to the oncology space, but an extension of a non-exclusive license to Regeneron's VelocImmune technology, potentially through 2023, signals the Japanese company's continued effort to become a significant player in the monoclonal antibody space
You may also be interested in...
2012 A Key Year For Astellas, Says New CEO Yoshihiko Hatanaka
Astellas is on the verge of significantly increasing its heretofore small presence in oncology in the U.S. and abroad as it, along with its partners, prepares to file one and possibly two NDAs, including for the promising prostate cancer treatment MDV3100.
Astellas, Eisai Tout Pipeline Updates In Face Of Patent Losses: Japanese Earnings Roundup (Part 1 Of 2)
TOKYO - Japanese pharma are responding to patent cliffs much like their Western counterparts, through lifecycle management, cost containment and increased focus on emerging markets. In Part 1 of PharmAsia News' roundup of the Japanese Q1 earnings season, Astellas and Eisai respond to patent loss of blockbuster products by highlighting product development milestones and patent extensions
Astellas, Eisai Tout Pipeline Updates In Face Of Patent Losses: Japanese Earnings Roundup (Part 1 Of 2)
TOKYO - Japanese pharma are responding to patent cliffs much like their Western counterparts, through lifecycle management, cost containment and increased focus on emerging markets. In Part 1 of PharmAsia News' roundup of the Japanese Q1 earnings season, Astellas and Eisai respond to patent loss of blockbuster products by highlighting product development milestones and patent extensions